Stockreport

Viracta Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Viracta Therapeutics, Inc.  (VIRX) 
PDF - Reprioritized resources to reduce costs and enhance focus on Nana-val’s development program in relapsed or refractory EBV-positive peripheral T-cell lymphoma (PTCL) - [Read more]